ClinicalTrials.gg
Active, not recruitingNCT06501066Updated Jul 15, 2024

Mesenchymal Stem Cells for Frailty Syndrome

A Phase 1/2 interventional study of umbilical cord mesenchymal stem cells in Pathologic Processes, sponsored by Meribank Biotech Co., Ltd.. Active, not recruiting at 2 sites in Taiwan. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2024-07-15.

Primary conditionFrailtyRegistry: Pathologic ProcessesReclassifiedWhy we changed it
Registry
Pathologic Processes — the first condition term the registry derived for this study.
ClinicalTrials.gg
Frailty
Why
  1. The study's title name Frailty, a narrower term within Pathologic Processes.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Meribank Biotech Co., Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 68 studies in Frailty with a site in Taiwan — 23 open to participants now, 24 under way, none of them phase 3. Frailty · Taiwan.

Enrollment
39th of 54
66 · median 94
Started
2024
with 6 others
Phase 1/2
Only one
of the 68
Primary completion
2026-12
later than 13 of 23 live
Registered
45th of 68
by date

Among the 68 studies in Frailty with a site in Taiwan, this one is the 39th largest by enrollment of the 54 interventional ones that give a count, is one of 7 that started in 2024, is the only one in phase 1/2, reaches primary completion later than 13 of the 23 other live ones, and was the 45th registered.

Frailty

1,287 studies on the registry are indexed under Frailty; 454 are open to participants now.

Browse Frailty studies →

Open to participants now

23 of the 68 studies in Frailty with a site in Taiwan are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 301 Frailty studies recruiting now, 236 (78%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 67 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Frailty with a site in Taiwan, or all of them as a file.
02

Study summary

This Phase I/II study is designed to evaluate the efficacy and safety of UMC119-06-05, an allogeneic umbilical cord mesenchymal stem cells, in older adults with frailty syndrome. This study will also seek to determine the long-term safety and clinical outcomes of UMC119-06-05 in subjects with frailty syndrome, which will provide information for subsequent clinical trials with UMC119-06-05.

Read the detailed description

Frailty is a disorder of several inter-related physiological systems, including genetic and environmental factors in combination with epigenetic mechanisms, which regulate the differential expression of genes in cells and could be especially important in ageing. Frailty syndrome characterized by a progressive decline in health and clinical symptoms of exhaustion, weight loss, a feeling of slowing down, and a decrease in functional capacity. Current interventions focus on interdisciplinary approaches which include nutritional supplementation, physical exercise, and cognitive intervention. The lack of standardized treatment of the disease resulted in the increasing number of elders diagnosed with frailty. Therefore, development of new therapeutic modalities to improve the clinical outcomes and prognosis of frailty syndrome in adult patients is of urgent need. Recently, preclinical and clinical studies support a cell-based, regenerative treatment strategy i.e., allogenic umbilical cord mesenchymal stem cell therapy may represent a novel therapy for aging frailty. This clinical trial is a phase I/II study. Phase I is an open-label study and all eligible subjects will receive a single-dose IV infusion of UMC119-06-05. Phase II study is a randomized, placebo-controlled, single-blind study and half of eligible subjects will receive a single-dose IV infusion of UMC119-06-05, the others will receive placebo.

03

Conditions studied

  • Pathologic Processes

Browse trials for

Keywords

  • Frailty
  • aging
  • mesenchymal stem cells
04

In context

Frailty Reclassified

1,287 studies on the registry are indexed under Frailty; 454 are open to participants now.

This study's enrollment of 66 is below the median of 82 across 769 interventional studies indexed under Frailty.

Browse Frailty studies →

Lead sponsor

Meribank Biotech Co., Ltd. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Compared within Frailty, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pathologic Processes. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects will be eligible for enrollment in the study only if they meet ALL of the following criteria:

  1. Subjects of age ≥ 65 years old at screening.
  2. Subjects show signs of frailty as assessed by CHS frailty Scores ≥ 1 at screening.
  3. Subjects with body weight between 40 kg to 90 kg.
  4. Subjects have received standard of care treatment (including exercise and nutritional supplementation) for FS for at least 30 days prior to the study.
  5. Subject is willing to provide written to participate in the study after reading the informed consent form and the information provided.

Exclusion criteria

Exclusion Criteria:

Subjects will be eligible for enrollment in the study only if they meet NONE of the following criteria:

  1. Subjects unwilling or unable to perform any of the assessments required by endpoint analysis.
  2. Subjects who have a significant comorbid medical condition(s), as judged by the investigator, including, but not limited to:

    1. Confirmed diagnosis of disabling neurologic disorder, including but not limited to Parkinson's disease, Amyotrophic lateral sclerosis, Stroke, or dementia, that significantly impact the assessments for endpoint analysis;
    2. Severe kidney disease requiring hemodialysis or peritoneal dialysis;
    3. Advanced liver disease such as hepatitis or liver cirrhosis;
    4. Severe congestive heart failure ( [NYHA] class 3 and 4);
    5. disease (rheumatoid arthritis, psoriasis/psoriatic arthritis, multiple sclerosis, systemic lupus erythematosus, etc.);
    6. Hearing or visual impairment that significantly impact the assessments for endpoint analysis;
    7. Pulmonary dysfunction requiring therapy or O2 supplementation
    8. Uncontrolled metabolic diseases including type II diabetes mellitus ( [HbA1c] > 8.5%)
  3. Subjects carry history of of any organ system (other than curatively treated localized basal or squamous cell carcinoma of the skin, cervical carcinoma in situ) within 5 years prior to the screening visit.
  4. Subjects using chronic high dose of steroid (> 5 mg prednisolone or equivalent), therapy, or TNF-α antagonists.
  5. Subjects with (HIV), active virus (HBV) or virus (HCV) infections.
  6. Subjects with known allergy or to any component of the formulation (normal saline, human serum albumin, or dimethyl sulfoxide).
  7. Subjects who have participated in another clinical study of new therapies within 3 months before the study drug administration.
  8. Subjects who have received any other stem cell therapy within 12 months before the study drug administration.
  9. Subjects have a history of moderate to severe substance use disorder (including alcohol, cannabis, hallucinogens, inhalants, opioids, sedatives/hypnotics/anxiolytics, and stimulants [e.g., amphetamine-type substance, cocaine]) based on (DSM-5) within the past 3 years.
  10. Subjects who have any hospitalization record within one month before the study drug administration (except for the scheduled admission in this study, if required).
  11. Subjects who have dramatic change in their standard of care treatment (including exercise and nutritional supplements) for improvement of frailty within one month prior to study treatment, as judged by the investigator.
  12. Any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Phase I Treatment Arm

    umbilical cord mesenchymal stem cells, 100×10\^6 cells/subject, single treatment by intravenous infusion in phase I.

    Biological: umbilical cord mesenchymal stem cells

  • Experimental
    Phase II Treatment Arm

    umbilical cord mesenchymal stem cells, 100×10\^6 cells/subject, single treatment by intravenous infusion in phase II.

    Biological: umbilical cord mesenchymal stem cells

  • Placebo comparator
    Phase II Placebo Arm

    Peripheral IV infusion of placebo at baseline.

    Biological: umbilical cord mesenchymal stem cells

Interventions

07

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs)/ Serious Adverse Events (SAEs).

    Phase I : Incidence of any treatment-emergent serious adverse events (SAE), defined as the composite of: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities.

    Time frame: Up to 12 months through study

  2. Incidence of withdrawals due to adverse events

    Phase I: Incidence of any treatment-emergent serious adverse events (SAE), defined as the composite of: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities.

    Time frame: Up to 12 months through study

  3. vital signs

    Phase I: change in vital signs

    Time frame: Up to 12 months through study

  4. physical examination

    Phase I: change in physical examination

    Time frame: Up to 12 months through study

  5. clinical laboratory test results

    Phase I: change in clinical laboratory test results

    Time frame: Up to 12 months through study

  6. electrocardiogram

    Phase I: change in electrocardiogram

    Time frame: Up to 12 months through study

Secondary outcomes

  1. Mean change from baseline in frailty status (Cardiovascular Health Study [CHS] frailty score

    CHS scale consists of five components-unintentional weight loss, exhaustion, low activity, weakness, and slowness

    Time frame: change from baseline to Day 91, Day 181, and Day 361

  2. Mean change from baseline in grip strength

    Hand grip strength as assessed by a dynamometer. Grip strength is recorded (in mmHg) three times for each hand.

    Time frame: change from baseline to Day 91, Day 181, and Day 361

  3. Mean change from baseline in chair-stand test

    a subject is able to transfer from a seated to a standing position and back to sitting five times

    Time frame: change from baseline to Day 91, Day 181, and Day 361

  4. Mean change from baseline in muscle mass and bone density

    muscle mass and bone density will be measured using DXA

    Time frame: change from baseline to Day 91, Day 181, and Day 361

  5. Mean change from baseline in quality of life measured by change in SF-12

    a quality of life measure

    Time frame: change from baseline to Day 91, Day 181, and Day 361

08

Study locations

2 sites
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2024
First posted
Jul 15, 2024
StartActual
Jun 3, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Jul 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06501066
Lead sponsor
Meribank Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Jul 15, 2024
Start date
Jun 3, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 15, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solizmestrocel

Start the discussion